Literature DB >> 18256351

New boundaries for complement in renal disease.

Steven Sacks1, Wuding Zhou.   

Abstract

Complement is an important component of the innate immune system whose function is integrated with the adaptive immune response. Since complement proteins are produced in virtually any cell in the body, it is important to question which pools of complement are responsible for what actions. This is particularly so in the case of complement-mediated renal disease, where distinct sites may require individualized approaches for therapy. From experimental and clinical evidence to date, it seems that the circulating pool of complement underlies much of the pathology traditionally associated with glomerular disease, including capillary wall injury. In contrast, the renal tubulointerstitium is the domain of local synthesis of complement, notably the axial component C3, principally expressed by the tubular epithelium. This means that therapeutic targeting will have to ensure penetration of the interstitial space in certain disorders. Likewise, monitoring of disease activity may benefit from evaluating this extravascular pool. Therapeutic and diagnostic applications in human disease are already taking this into account, with transplantation leading the way.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256351     DOI: 10.1681/ASN.2007101121

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  16 in total

1.  Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis.

Authors:  Siranush A Sargsyan; Natalie J Serkova; Brandon Renner; Kendra M Hasebroock; Brian Larsen; Conrad Stoldt; Kim McFann; Matthew C Pickering; Joshua M Thurman
Journal:  Kidney Int       Date:  2011-09-28       Impact factor: 10.612

2.  Renal C3 complement component: feed forward to diabetic kidney disease.

Authors:  Katherine J Kelly; Yunlong Liu; Jizhong Zhang; Jesus H Dominguez
Journal:  Am J Nephrol       Date:  2015-01-30       Impact factor: 3.754

3.  Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.

Authors:  Min Pan; QiongXiu Zhou; ShuBei Zheng; XiaoHan You; Duo Li; Ji Zhang; ChaoSheng Chen; FeiFei Xu; ZhanYuan Li; ZhiHong Zhou; JianNa Zhang
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

4.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

Review 5.  Evolving paradigms that determine the fate of an allograft.

Authors:  J S Bromberg; P S Heeger; X C Li
Journal:  Am J Transplant       Date:  2010-02-25       Impact factor: 8.086

6.  Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Daniel Ricklin; Richard J Smith; John D Lambris
Journal:  Trends Immunol       Date:  2017-04-14       Impact factor: 16.687

7.  Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis.

Authors:  Guang-qun Xing; Min Chen; Gang Liu; Xin Zheng; Jie E; Ming-hui Zhao
Journal:  J Clin Immunol       Date:  2009-11-07       Impact factor: 8.317

8.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

9.  Renal retention of lipid microbubbles: a potential mechanism for flank discomfort during ultrasound contrast administration.

Authors:  Ya Ni Liu; Jaspreet Khangura; Aris Xie; J Todd Belcik; Yue Qi; Brian P Davidson; Yan Zhao; Sajeevani Kim; Yoichi Inaba; Jonathan R Lindner
Journal:  J Am Soc Echocardiogr       Date:  2013-09-12       Impact factor: 5.251

Review 10.  The complement cascade and renal disease.

Authors:  Katarzyna Kościelska-Kasprzak; Dorota Bartoszek; Marta Myszka; Marcelina Zabińska; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-09-13       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.